I am finally back and the sector appears to have pulled back a little. I do not see this a particularly bad pull back as it looks to have closed a gap and bounced off of it. In my mind, it appears to be setting up as a successful test of the recent breakout assuming […]
February 28th Biotech Update
The sector continues to hang out at these levels and my sense is that the longer we wait to go, the more likely we consolidate the move higher. I do find it a little odd that we have not seen a more clear move (up or down) but it likely means that this level will […]
January 15 Biotech Update
We are clearly not out of the woods for a correction but we should also remember that corrections can occur through price or time. In other words, most think of a correction as a retracement of a move higher and while that is most common, it can also occur through time where prices grind in […]
January 11 Biotech Update
Everyone continues to expect a pullback and yesterday looked like it would be the day that starts the correction but we ended up green again. This has been on the of the strongest JPM weeks I remember (at least from a price action perspective). Yesterday is another brick in the wall of the idea that […]
November 12 Biotech Update
A rough start to the week. The market just feels heavy and looks like it wants to break through the recent lows. It looked for a little like it wanted break from the downtrend and form a new channel higher but the week is not starting off like that is in the cards. Another leg […]
October 1 Biotech Update
Yet again another weekend is passed and yet again there are no major M&A. Yet again, it no longer seems to matter. A little different this morning is not a major outperformance by the large caps but it is still early. There is at least some little bit of news to start the week but […]
September 27th Biotech Update
We continue to see the disconnect between the IBB and XBI, where the large caps are outperforming the SMID. Given that the previous range break on the IBB did not hold, I suspect we will need greater SMID participation but it is not crazy to see investors first put money to work in large caps […]
September 24 Biotech Update
An interesting start to the week, although we still like real M&A or business development. Unlike previous weeks, however, there is actually some interesting news to discuss. The sector is green and outperforming the broader market but the move seems pretty isolated so ideally this green will broaden as the day continues. 1. The big […]
13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are a great idea generation tool, a starting place for due diligence, and way to get a peek at the focus of the best minds in […]
December 20 Biotech Update- Wrapping up the Year
It was a good day for the market and biotechs were strong once again. It seems like tax loss selling is winding down and selling volume is starting to dry up. So we are likely to have a positive bias for the rest of the year. It also helps that the news flow in biotechs […]
Catalyst Watch – Vol. 1, Edition 5 (10/22/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: VNDA: No change in strategy (See Vol. 1, Edition 2). […]
October 17- EOD
A mixed day in the market which was nice to see a day in which not all stocks were moving in the same direction. Obviously had some stock specific news with AMRN and the PSDV PDUFA and some more general biotech news. 1. AMRN was the stock of the day with about a 67% haircut […]
October 16- EOD
With the approach of an end (as temporary as it is likely to be) of the stalemate in Washington you thought we would be approaching the end of the macro driven market. While I think that is likely true, we still are going to have a knee jerk relief rally before it settles back down […]
Catalyst Watch – Vol. 1, Edition 4 (10/11/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Waiting for briefing docs… More to follow on this […]
Catalyst Watch – Vol. 1, Edition 3 (10/2/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Stock continues to climb (now at $6.85). No delay […]
Catalyst Watch – Vol. 1, Edition 2 (9/26/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: The stock is up slightly ($6.58) from our last […]
Catalyst Watch – Vol. 1, Edition 1 (9/20/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: Ticker: VNDA ($13.16) Catalyst: AdCom for Tasimelteon Date/Timing: November 14, 2013 CRG View: Bearish Cash: $151.9m […]
AMRN – Another Breakout – Chart Update
Amarin Corporation plc (AMRN) -Nasdaq Since my latest “Chart & TA” report AMRN – Running Up To The AdCom on Aug 30th, 2013. AMRN kept trading up and gained 4.7% , reaching the downtrend line (brown color on the chart) around $6.65. There we witnessed a real control’s war between the bulls and the bears around 12:15 […]
AMRN – Running Up To The AdCom
Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to breakout is the Brown downtrend line around $6.70 that will make the weekly resistance line at $7.56 as the next target. Expect some technical correction […]
Week’s Option Activity (8/19~8/22)
The following stocks had notable activity in their options during the past week: $AMRN (8/19): 5,000 OCT 7.0 strike Calls (stock at $6.00) were sold for 0.87 or $435,000 total proceeds. Seller makes money as long as stock trades below $7.87 by expiration. This trade may also be a current long stockholder selling Calls to […]
